Skip to content

Individualized treatment of chordoma by tumor vaccine: a clinical trial

Individualized treatment of chordoma by tumor vaccine: a clinical trial

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016628
Enrollment
Unknown
Registered
2018-06-14
Start date
2017-12-01
Completion date
Unknown
Last updated
2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chordoma

Interventions

conservative group:best of care
tumor vaccine group:vaccination

Sponsors

Shanghai Changzheng Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) chordoma patients aged 15-75 years; 2) imaging examination confirmed recurrence; 3) multiple recurrences and unsuitable for surgical treatment; 4) no serious cognitive impairment, no sensory aphasia, able to understand basic instructions; 6) no severe heart,brain and other organ diseases; 6) inform consent form signed.

Exclusion criteria

Exclusion criteria: 1) patients with severe heart,brain,kidney and autoimmune diseases; 2) patients with poor poor compliance.

Design outcomes

Primary

MeasureTime frame
overall survival;local progression free survival;visual analog scale score;Scale of quality of life;Frankel score;

Countries

China

Contacts

Public ContactJianru Xiao

Department of Orthopaedic Oncology, Shanghai Changzheng Hospital

jianruxiao83@163.com+86 13701785283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026